Androgen deprivation therapy added to radiation therapy (RT) for unfavorable-risk prostate cancer is not associated with an increased risk for cardiovascular mortality compared with RT alone, even among patients with preexisting cardiovascular disease, a study found.
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Camcevi in 137 adults with advanced prostate cancer.
The approval was based on data from the phase 2/3 OSPREY and phase 3 CONDOR trials that evaluated the diagnostic performance and safety of Pylarify injection.
Investigators compared the efficacy, safety, and costs of abiraterone, darolutamide, enzalutamide, and apalutamide in treating nmCRPC.
Men who take 5-alpha-reductase inhibitors while on active surveillance for prostate cancer are less likely to experience cancer progression, according to a new study
Black men with metastatic hormone-sensitive prostate cancer may have better outcomes if they receive enzalutamide rather than bicalutamide in combination with androgen deprivation therapy, data from a phase 2 trial suggests.
In a study, statin use was associated with a 36% decreased risk for death among men initiating androgen deprivation therapy for recurrent prostate cancer following primary or salvage radiation therapy.
Orgovyx is an oral nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist.
Orgovyx is an oral nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist.
Using a blood sample, the test is able to analyze more than 300 cancer-associated genes for alterations.
